✦ LIBER ✦

A health economic model to assess the cost-effectiveness of PEG IFN α-2a and ribavirin in patients with mild chronic hepatitis C

✍ Scribed by S. Gerkens; M. Nechelput; L. Annemans; B. Peraux; M. Mouchart; C. Beguin; Y. Horsmans

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated interferon alpha-2b (Peg-IFN α

✍ T. Oze; N. Hiramatsu; T. Yakushijin; M. Kurokawa; T. Igura; K. Mochizuki; K. Ima 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

Efficacy of peg-interferon-α-2a plus rib

✍ Dong Hyun Sinn; Su Rin Shin; Jae Sook Kil; Jeong Kim; Geum-Youn Gwak; Moon Seok 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB

Using competence network collaboration a

✍ Uwe Siebert; Gaby Sroczynski; Jürgen Wasem; Wolfgang Greiner; Ulrike Ravens-Sieb 📂 Article 📅 2005 🏛 Springer 🌐 French ⚖ 261 KB

A prospective assessment of an ‘a la car

✍ C. D'Arondel; M. Munteanu; J. Moussalli; V. Thibault; S. Naveau; A. Simon; D. Me 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

A randomized trial of pegylated-interfer

✍ A. CIANCIO; A. PICCIOTTO; C. GIORDANINO; A. SMEDILE; M. TABONE; A. MANCA; G. MAR 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB

Prediction of nonSVR to therapy with peg

✍ E. Lukasiewicz; M. Gorfine; L. S. Freedman; J.-M. Pawlotsky; S. W. Schalm; C. Fe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB